Showing 2951-2960 of 5771 results for "".
- Science Corporation: PRIMA Clinical Trials Show Restoration of "Form Vision"https://modernod.com/news/science-corporation-announces-breakthrough-in-retinal-implant-technology-prima-clinical-trials-show-restoration-of-form-vision/2482509/Science Corporation, a developer in brain-computer interface (BCI) technology, has announced preliminary results from clinical trials of its PRIMA retina implant. This technology has demonstrated the ability to restore what the company is calling 'form vision' in patients suffer
- Ocuphire Acquires Gene Therapy Company Opus Geneticshttps://modernod.com/news/ocuphire-acquires-gene-therapy-company-opus-genetics/2482508/Ocuphire Pharma announced an all-stock acquisition of Opus Genetics, a clinical-stage gene therapy company specializing in inherited retinal diseases (IRDs). As part of the deal, the combined company will be renamed Opus Genetics, effective October 23, 2024, and will begin trading under the
- Life Biosciences Presents New Data on Novel Gene Therapy at AAOhttps://modernod.com/news/life-biosciences-presents-new-data-on-novel-gene-therapy-at-aao/2482505/Life Biosciences announced new data at the 2024 American Association of Ophthalmology (AAO) annual meeting on its gene therapy for optic neuropathies. According to Life Biosciences, the data replicates earlier findings in nonhuman primates (NHPs) and provides insights into the dosing and tim
- Oculis Accelerates Enrollment for Phase 3 DIAMOND Trials of OCS-01 Eye Drops in DMEhttps://modernod.com/news/oculis-accelerates-enrollment-for-phase-3-diamond-trials-of-ocs-01-eye-drops-in-diabetic-macular-edema/2482504/Oculis announced significant progress in patient enrollment for both phase 3 DIAMOND trials of OCS-01 eye drops in diabetic macular edema (DME). The DIAMOND program, designed to assess the efficacy and safety of OCS-01, an investigational eye drop, has enrolled about 70% of patients in the phase
- Regenxbio Reports Positive Phase 2 Data on ABBV-RGX-314 for Bilateral Wet AMDhttps://modernod.com/news/regenxbio-reports-positive-phase-2-data-on-abbv-rgx-314-for-bilateral-wet-amd/2482503/Regenxbio announced results from the phase 2 fellow eye sub-study evaluating the subretinal delivery of ABBV-RGX-314, a gene therapy candidate, in patients with bilateral wet age-related macular degeneration (AMD). The data was presented at the American Academy of Ophthalmology (AAO) me
- Johnson & Johnson to Showcase Tecnis Odyssey IOL and Present New Research at AAO 2024https://modernod.com/news/johnson-johnson-to-showcase-tecnis-odyssey-iol-and-present-new-research-at-aao-2024/2482501/Johnson & Johnson will highlight its latest innovations in eye health during the 2024 American Academy of Ophthalmology (AAO) annual meeting, taking place from October 18-21 in Chicago. Among the company's spotlight advancements is the Tecnis Odyssey IOL, a new presbyopia-correcting IOL t
- Exponential Increase in Anti-VEGF Treatments Linked to Higher Risk of Complications in Cataract Surgery, Study Findshttps://modernod.com/news/exponential-increase-in-anti-vegf-treatments-linked-to-higher-risk-of-complications-in-cataract-surgery-study-finds/2482498/In the largest study of its kind, Canadian researchers from the University of Toronto have identified a higher risk of complications in cataract surgery patients with a history of anti-VEGF injections. These findings will be presented this week at AAO 2024, the 128th annual meeting of the America
- Google’s Diabetic Retinopathy AI Model Licensed for Use in India and Thailandhttps://modernod.com/news/googles-diabetic-retinopathy-ai-model-licensed-for-use-in-india-and-thailand/2482497/Google announced the licensing of its diabetic retinopathy artificial intelligence (AI) model to healthcare providers and health-tech partners. According to Google, during the next 10 years, Forus Health, AuroLab, and Perceptra will aim to deliver a combined 6 million AI-supported scree
- Eye Health America and Verséa Ophthalmics Form Preferred Supply Partnershiphttps://modernod.com/news/eye-health-america-and-versea-ophthalmics-form-preferred-supply-partnership/2482496/Eye Health America (EHA) announced a preferred partnership supply agreement with Verséa Ophthalmics. Terms of the agreement were not disclosed. EHA is an ophthalmic provider offering strategic and operational support to practice groups and ambulatory surgery centers (ASCs) in the
- Ikerian and RetinAI Secure $8M Financing to Drive AI Healthcare Innovationhttps://modernod.com/news/ikerian-and-retinai-secure-8m-financing-to-drive-ai-healthcare-innovation/2482494/Switzerland-based Ikerian AG and its subsidiary RetinAI US, announced the successful first close of their Series B financing round, securing USD $8 million (CHF 6.73 million). With the newly secured funding, Ikerian said it is set to fast-track the development of its flagship produ